MSA
BCRX icon

Mason Street Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mason Street Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-64,300
Closed -$782K – 1538
2014
Q4 		$782K Buy
+64,300
New +$710K 0.01% 1255

Other funds holding BCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Mason Street Advisors's BCRX Position: Q1 2015 in Review

Mason Street Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2015, closing a stake of 64,300 shares — an estimated $782K sold.

Mason Street Advisors first reported a position in BCRX in Q4 2014 and held it in 1 quarter. The position peaked at $782K in Q4 2014. 98 funds tracked by Wall St. Rank hold BCRX as of Q1 2015.

  • Mason Street Advisors reported no remaining BioCryst Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Mason Street Advisors sold 64,300 BioCryst Pharmaceuticals shares in Q1 2015, an estimated $782K.
  • Mason Street Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Mason Street Advisors's BioCryst Pharmaceuticals position peaked at $782K in Q4 2014.
  • 98 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2015.

Based on Mason Street Advisors's 13F filing for Q1 2015, filed 15 May 2015.